0001062993-23-022977.txt : 20231220 0001062993-23-022977.hdr.sgml : 20231220 20231220175155 ACCESSION NUMBER: 0001062993-23-022977 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231218 FILED AS OF DATE: 20231220 DATE AS OF CHANGE: 20231220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciaffoni Joseph CENTRAL INDEX KEY: 0001443841 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 231502369 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-12-18 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001443841 Ciaffoni Joseph C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 1 1 0 0 President and CEO 1 Common Stock 2023-12-18 4 M 0 27798 21.34 A 302798 D Common Stock 2023-12-18 4 S 0 27798 30.0358 D 275000 D Common Stock 2023-12-19 4 M 0 14516 21.34 A 289516 D Common Stock 2023-12-19 4 S 0 14516 30.0318 D 275000 D Common Stock 2023-12-20 4 M 0 26454 21.34 A 301454 D Common Stock 2023-12-20 4 S 0 26454 30.4003 D 275000 D Stock Option (Right to Purchase) 21.34 2023-12-18 4 M 0 27798 0 D 2030-02-05 Common Stock 27798 62202 D Stock Option (Right to Purchase) 21.34 2023-12-19 4 M 0 14516 0 D 2030-02-05 Common Stock 14516 47686 D Stock Option (Right to Purchase) 21.34 2023-12-20 4 M 0 26454 0 D 2030-02-05 Common Stock 26454 21232 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.185, inclusive. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64, inclusive. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. /s/ Colleen Tupper as Attorney-In-Fact For Joseph Ciaffoni 2023-12-20